A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
Beta variant
SARS-CoV-2
antivirals
molnupiravir
mouse model
nirmatrelvir
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
24 08 2022
24 08 2022
Historique:
pubmed:
5
8
2022
medline:
27
8
2022
entrez:
4
8
2022
Statut:
ppublish
Résumé
Ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lacks the intrinsic ability to bind to the mouse ACE2 receptor, and therefore establishment of SARS-CoV-2 mouse models has been limited to the use of mouse-adapted viruses or genetically modified mice. Interestingly, some of the variants of concern, such as the Beta B.1.351 variant, show an improved binding to the mouse receptor and hence better replication in different wild-type (WT) mouse species. Here, we describe the establishment of a SARS-CoV-2 Beta B.1.351 variant infection model in male SCID mice as a tool to assess the antiviral efficacy of potential SARS-CoV-2 small-molecule inhibitors. Intranasal infection of male SCID mice with 10
Identifiants
pubmed: 35924921
doi: 10.1128/jvi.00758-22
pmc: PMC9400483
doi:
Substances chimiques
Antiviral Agents
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0075822Références
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):
pubmed: 33658332
J Med Virol. 2022 Jul;94(7):3223-3232
pubmed: 35322439
Natl Sci Rev. 2020 Nov 24;8(2):nwaa285
pubmed: 34676093
Science. 2021 Dec 24;374(6575):1586-1593
pubmed: 34726479
Nature. 2020 Oct;586(7830):560-566
pubmed: 32854108
Cell Host Microbe. 2021 Apr 14;29(4):508-515
pubmed: 33789086
Nat Commun. 2021 Sep 27;12(1):5654
pubmed: 34580297
Nat Commun. 2022 Feb 15;13(1):719
pubmed: 35169114
Viruses. 2021 Nov 11;13(11):
pubmed: 34835069
Transbound Emerg Dis. 2014 Dec;61(6):e89-91
pubmed: 23480064
Cell Rep. 2022 Feb 15;38(7):110387
pubmed: 35134331
J Gen Virol. 2002 Aug;83(Pt 8):1887-1896
pubmed: 12124452
Cell. 2020 Aug 6;182(3):744-753.e4
pubmed: 32553273
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Science. 2020 Sep 25;369(6511):1603-1607
pubmed: 32732280
Sci Transl Med. 2019 Oct 23;11(515):
pubmed: 31645453
Nature. 2020 Jul;583(7818):830-833
pubmed: 32380511
EBioMedicine. 2021 Nov;73:103643
pubmed: 34689086
Nat Commun. 2020 Nov 17;11(1):5838
pubmed: 33203860
J Infect Dis. 2021 Sep 1;224(5):749-753
pubmed: 34244768
EBioMedicine. 2021 Jun;68:103403
pubmed: 34049240
Antimicrob Agents Chemother. 2001 Jan;45(1):84-7
pubmed: 11120949
Nature. 2022 Mar;603(7902):687-692
pubmed: 35062015
Nature. 2022 May;605(7909):206
pubmed: 35513455
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
Wellcome Open Res. 2021 May 19;6:121
pubmed: 34095513